Mankind Pharma Ltd Peer Comparison

Mankind Pharma Faces ₹183.11 Crore Tax Demand

 Copy Link

The cumulative demand, including interest charges, is ₹183.11 crore.

Mankind Pharma Merges Three Subsidiaries

 Copy Link

The merger took effect on March 29, 2025, after all necessary regulatory approvals were obtained.

Mankind Pharma Faces ₹111.68 Crore Tax Demand, Plans to Appeal

 Copy Link

The tax adjustments pertain to Section 80IC/80IE, which involves deductions for businesses in special economic zones, and a disallowance of certain expenditures under Section 37(1) of the Act.

Top Stocks for Today - 24th January 2025

 Copy Link

Here are some of the stocks that may see significant price movement today: Indus Towers, Dr Reddy’s Laboratories, Mankind Pharma, etc.

Mankind Pharma Q3 Profit Falls 16%, Revenue Jumps 24%

 Copy Link

The company reported a good growth in EBITDA of 36.8% to ₹830 crore in the quarter against ₹606.5 crore in Q3 FY24.

Mankind Pharma Secures ₹5,000 Crore NCDs by Pledging 56.31% Stake in BSV

 Copy Link

The NCDs issued are categorized, rated, secured, redeemable, and transferable, distributed across three series.

Mankind Pharma, Innovent Join Forces for Cancer Care

 Copy Link

According to the National Cancer Registry Programme, cancer is expected to cause 29.8 million DALYs by 2025, making it a serious health issue in India.

Mankind Pharma Secures ₹3,000 Crore via QIP for Growth

 Copy Link

The issue price includes a premium of ₹2,519 per share, aggregating a total of ₹2,999.99 crore.

Mankind Pharma Sees 30% Profit Surge in Q2

 Copy Link

Revenue from operations grew by 13.6% YoY, totaling ₹3,076.5 Crore, up from ₹2,708.1 Crore in Q2 of the previous fiscal.

Top stocks for today - 6th November 2024

 Copy Link

Here are some of the stocks that may see significant price movement today: Dr Reddy’s, Hindustan Zinc, Titan Company, etc.